Adenoviral vectors are considered to be good gene delivery vectors for cancer gene therapy due to their wide host tissue range and cell cycle-independent infectivity. However, the disadvantages include the lack of specificity for cancer cells and the high liver accumulation in vivo. The human CXCR4 gene is expressed at high levels in many types of cancers, but is repressed in the liver. We explored the CXCR4 promoter as a candidate to restrict adenoviral transgene expression to tumor cells with a low expression in host tissues. The luciferase activities in multiple cancer cell lines infected with recombinant adenovirus reAdGL3BCXCR4 or the control vector reAdGL3BCMV revealed that the CXCR4 promoter exhibited relatively high transcriptional activity in a breast cancer cell line, MDA-MB-361, and two ovarian cancer cell lines, OVCAR-3 and SKOV3. ip1, 65% (P¼0.0087), 16.7% (P¼0.1) and 20% (P¼0.0079) compared to that of the CMV promoter, respectively, and low expression, 4.9 and 0.1%, respectively, in both normal cell lines HFBC and HMEC. In addition, CXCR4 had a low expression of luciferase (0.32%) compared to that of the CMV promoter in mouse liver in vivo. The data also revealed that the CXCR4 promoter was a stronger tumor-specific promoter (TSP) than the Cox-2M promoter in primary melanomas obtained from two patients. The CXCR4 promoter is shown to have a 'tumor-on' and 'liver-off' status in vitro and in vivo, and CXCR4 may prove to be a good candidate TSP for cancer gene therapy approaches for melanoma and breast cancers.
Introduction
Current conventional therapies have improved the outcome in many cancer contexts. However, mortality worldwide from many malignancies remains still high. Thus there remains the need to identify novel therapeutic paradigms for cancer. In this regard, gene therapy represents a novel approach for cancer treatment. To date, gene therapy approaches have been generally unsuccessful. One of the key factors limiting realization of the potential of cancer gene therapy has been the poor tumor transduction efficiency of currently available vector systems and their nonspecific transduction of normal tissues with attendent toxicity. 1, 2 Various approaches have been developed to enhance the infectivity of current vector systems in order to address poor tumor cell transduction efficiency. In parallel, strategies have been developed to enhance the transcription selectivity of current vector systems for tumor cells in order to address the concerns regarding normal tissue transfection and toxicity. In this regard, both transductional and transcriptional targeting strategies have been employed. [3] [4] [5] [6] [7] [8] With transductional targeting, vector systems are modified in a manner to achieve tumor cell transduction specificially. With transcriptional targeting, gene expression is controlled such that the gene of interest is under the control of a promoter that maintains a 'tumor-on' status, and a 'normal tissue-off' status. Whereas a number of promoters have been explored in the context of cancer gene therapy, only a few exhibit an optimal profile of activity and specificity.
Chemokines are a family of relatively low molecular weight proteins that mediate cell migration. Their classification is based on the sequence of arranged cysteine groups, with four subsets of chemokines reported to date. The a subset is characterized by an intervening amino acid between two cysteines and is thus termed CXC chemokines. 9 One a-chemokine receptor gene, CXCR4, has been mapped to chromosome 2 (2q21) and contains two exons of 103 and 1563 base pairs (bp) interrupted by a 2132 bp intron precisely between codons 5 and 6 of the coding sequences. 10 Recently, Mü ller et al 11 have demonstrated that CXCR4 expression is markedly upregulated in breast cancer cells, but undetectable in normal mammary epithelial cells. Furthermore, recent evidence points to the SDF-1a-CXCR4 axis as playing a role in progression to metastasis in a number of other tumor contexts. [12] [13] [14] [15] In this study, we evaluate the potential utility of CXCR4 as a tissue-specific promoter for cancer gene therapy.
In this study, we employed a recombinant adenoviral vector (reAdGL3BCXCR4) expressing luciferase under the control of the CXCR4 promoter to the end of transcriptional targeting of tumor cells. To design and construct the recombinant adenoviral vector reAdGL3BCXCR4, a DNA construct encoding the luciferase gene from a vector pGL3B (Invitrogen, Carlsbad, CA, USA) was fused in-frame to the deleted E1 region of adenoviral type 5 vector. The expression of this reporter gene was controlled under both a 279 bp human CXCR4 promoter and a simian virus 40 (SV40) polyadenylation (poly-A) signal, inserted upstream and downstream of luciferase gene, respectively. Thus, the levels of luciferase expression reflect the activity of the CXCR4 promoter. The structures of the reAdGL3BCXCR4 and a positive control, reAdGL3BCMV, are shown in Figure 1 .
To analyze the activity of the CXCR4 promoter in the adenoviral-mediated gene expression context, eight cancer cell lines were tested in this study, including breast, ovarian, pancreatic and melanoma, along with two normal controls, human fibroblast cell (HFBC) and human mammary epithelial cell (HMEC). A total of 5 Â 10 4 cells of each one were infected at an MOI of 50 PFU/cell with the recombinant adenovirus reAdGL3BCXCR4 or the control vector reAdGL3BCMV, whereby the expression of reporter gene, luciferase, was driven by the CXCR4 promoter or the CMV promoter, respectively. Figure 2 shows the CXCR4 promoter activity as a percentage of the CMV promoter, used as a positive control to normalize the activity of the CXCR4 promoter. Figure 2 illustrates that the CXCR4 activity is remarkably high in the following cancer cell lines, breast (MDA-MB-361) and ovarian (OVCAR-3 and SKOV3. ip1), 65% (P¼0.0087), 16 .7% (P¼0.1) and 20% (P¼0.0079) of that induced by the CMV promoter, respectively. A pancreatic cancer cell line, BxPC-3, exhibited a slightly high activity of the CXCR4 promoter (5.5%) compared to that of the CMV promoter. However, the difference was not significant. In the rest of the cell lines, luciferase activities were lower than that of the normal controls, HFBC, which had 4.9% of that of the CMV promoter. The other normal cell line, HMEC, had 0.1% luciferase activity of the CMV promoter. These data show that the CXCR4 promoter is 'on' in some of the cancer cell lines, especially breast and ovarian cancers.
To measure the activity of the CXCR4 promoter in major organs of mouse, reAdGL3BCMV and reAdGL3BCXCR4 were administered intravenously to mice, and the major organs, including liver, lungs, Figure 1 Recombinant adenovirus vectors that express firefly luciferase were constructed through homologous recombination in E. coli using the AdEasy system. 20 All viruses used in these experiments encode a reporter gene, luciferase, regulated by a promoter, CXCR4, CMV or Cox-2M, which drives the reporter expression, inserted in the E1-deleted region of adenoviral vector backbone. A clone, pBSKCAT/CXCR4 1B/4-1 [5 0 D3], which contains an inserted 279 bp DNA fragment of the CXCR4 promoter (À191 to þ 88, containing transcription start site), was a kind gift from Dr Nelson L Michael. 10 The CXCR4 promoter region was excised with KpnI/HindIII from this clone and subcloned into pGL3/Basic vector (Invitrogen, Carlsbad, CA, USA) to generate pGL3BCXCR4, which contains a 279 bp human CXCR4 promoter, a firefly luciferase cDNA, as a reporter gene, and simia virus 40 (SV40) polyadenylation (poly-A) signal. Then, a KpnI-SalI fragment from pGL3BCXCR4 was cloned into pShuttle vector (Quantum, Montreal, Quebec, Canada) to generate pShuttleGL3BCXCR4. Next, homologous recombination was performed with the pAdEasy genome (Quantum) in BJ5183 cells to create a new recombinant adenovirus, AdGL3BCXCR4. Two control recombinant adenoviruses, AdGL3BCMV and AdGL3BCox2M, E1-and E3 deleted recombinant adenoviruses expression luciferase from the CMV enhancer/ promoter, and the 942 bp Cox-2 promoter, 6 respectively. The viruses were propagated in the adenovirus-packaging cell line 293 and purified by double CsCl density gradient ultracentrifugation, followed by dialysis against PBS with 10% glycerol. Physical particle concentration (viral particles (vp)/ml)) was determined by OD 260 reading, and biological activity (plaque-forming units (PFU)/ml)) was determined by standard plaque assay on 293 cells. After splitting, the cells were maintained in M199 medium with glutamine, supplemented with 5% FBS and penicillin/streptomycin. The other normal cell line, human mammary epithelial cells (HMEC), was purchased from Cambrex BioScience company (Walkersville, MD, USA) and cultured in the medium specially purchased from the same company. The adenoviral transformed human embryonic kidney cell line 293 was cultured in DMEM-F12 medium containing 10% FBS, 2 mM glutamine and penicillin (100 IU/ml)/streptomycin (100 mg/ml) at 371C in a humidified 5% CO 2 atmosphere. For determination of transcriptional activity of the CXCR4 promoter in recombinant adenovirus, reAdGL3BCXCR4, 5 Â 10 4 cells of each cell line were plated in 24-well tissue plates. The next day, cells were infected with reAdGL3BCMV or reAdGL3BCXC4 at an MOI of 50 PFU/cell in 200 ml of individual growth medium containing 2% FBS (infection medium). The infection medium was replaced by the fresh medium after 3 h. At 48 h after infection, luciferase activity was determined using the Reporter Lysis Buffer and Luciferase Assay System of Promega (Madison, WI, USA) following the manufacturer's protocol. Experiments were performed in triplicates and data were standardized with RLU values of the CMV promoter. Figure 3 shows the CXCR4 promoter-driven luciferase activity as a percentage of the CMV promoter-driven luciferase activity (set luciferase activity of the CMV promoter as 100%). The statistical analysis of the data was performed by t-test with Statistical Analysis Software 8.2 (SAS 8.2). A value of Po0.05 was considered statistically significant. **Po0.01; *Po0.05.
Transcriptional targeting via the CXCR4 promoter
ZB Zhu et al spleen, kidneys, heart, intestine and muscle, were harvested after 2 days, and luciferase activity was determined ( Figure 3 ). The CMV promoter activity was relatively high in the liver and spleen, and low in the kidney and intestine. The CXCR4 promoter activity was within the same order of magnitude in all organs, except the heart and muscle, which had a relatively low promoter activity of CXCR4. In the liver, the mean luciferase activity with AdGL3BCXCR4 (91 961 RLU/mg protein, n¼5) was extremely low, 0.3% of the activity of AdGL3BCMV. The activity in spleen of AdGL3BCXCR4 (227 223 RLU/mg protein, n¼5) was 3.8% of AdGL3BCMV. The CXCR4 promoter activity in the lung was 23% (6925 RLU/mg protein, n¼5) of the activity of AdGL3BCMV. In the heart, the activity of the CXCR4 promoter was 0.3% of AdGL3BCMV (507 RLU/mg protein for AdGL3BCXCR4, n¼5). Both activities of luciferase were barely measurable in the intestine and muscle, and were 11 and 0.19% of AdGL3BCMV (299 and 800 RLU/mg protein for AdGL3BCXCR4, n¼5), respectively. Interestingly, the CXCR4 promoter activity ratio was high in the kidney, indicating 44% activity of AdGL3BCMV (4401 RLU/mg protein for AdGL3BCXCR4, n¼5), although its absolute amount was only 4.8% of that in the liver. However, it is very possible that the CXCR4 promoter might be a good candidate as a tissue-specific promoter for renal cancer gene therapy (Y Haviv, manuscript submitted). 16 These results indicate that the CXCR4 promoter is specifically repressed in the murine liver.
In our analysis using established cell lines, the activity of CXCR4 promoter in an adenovirus construct was remarkably high in some cell lines, such as MDA-MB-361 and SKVO3. ip1 (65% and 20%) compared to CMV promoter. Human trials, however, have suggested a discrepancy between cell lines and clinical gene transfer efficiency. 17, 18 Therefore, to further clarify their function in a system that closely resembles the in vivo situation, experiments were performed using these promoters with primary melanoma cells from two patients. Nettelbeck et al 19 recently demonstrated the activity of the Cox-2 Figure 3 To analyze the CXCR4 promoter transcriptional activity in mouse organs, C57BL/6 mice were injected with 5 Â 10 8 PFU of AdGL3BCXCR4 or AdGL3BCMV intravenously via tail vein. After 2 days, major organs, including liver, lungs, kidneys, spleen, intestine, heart and muscle, were harvested to measure luciferase expression. All the organs were rapidly frozen on dry ice-ethanol bath and stored at À801C until assayed. On the day of analysis, the organs were ground into fine powder with a pestal and mortar in an ethanol/dry ice bath. The tissue powders were lysed with Cell Culture Lysis Buffer (Promega, Madison, MI, USA) and, after three rounds of freezing and thawing followed by centrifugation, the recovered supernatants were analyzed with the Luciferase Assay System (Promega) on the Luminocount (Packerd). The figure shows the luciferase activity in vivo by using the means (n¼5) of relative light units (RLU) in major mouse organs 48 h after intravenous administration of the CXCR4 or CMV promoter-driven luciferase expression viruses. reAdGL3CMV, white; reAdGL3CXCR4, black. Figure 4 Primary melanomas P-A and P-B were obtained from two patients and used in this study. Cells were cultured in RPMI containing 10% FCS (BioWittacher, Walkersville, MD, USA), 20 mg/ml gentamycin and 2 mM glutamine. Cells were grown at 371C in a humidified atmosphere and 5 Â 10 4 primary melanoma cells were plated in 24-well plates. The next day, cells were infected with reAdGL3BCMV, reAdGL3BCXC4 or reAdGL3BCox-2M at an MOI of 50 PFU/cell in 200 ml of RPMI1604 containing 2% FBS (infection medium). The infection medium was replaced by the fresh medium after 3 h. At 48 h after infection, luciferase activity was determined in two primary melanoma cell lines as mentioned above. Messenger RNA levels of CXCR4 gene in two primary melanoma cell lines and two normal cell lines (HFBC and HMEC) were determined by real-time PCR. For real-time PCR, total cellular RNA was extracted from 5 Â 10 5 cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), then the RNA samples were treated with DNase to remove the possible contaminated DNA. The fluorescent TaqMan probe (6FAM-ACACTTCAGATAACTACACCGAG GAAATGGGC) and the primer pair (forward primer, AACCAGCGGT TACCATGGAG; reverse primer, CTTCATGGAGTCATAGTCCCCTG) used for real-time PCR in the analysis of the CXCR4 mRNA were designed by the Primer Express 1.0 (Perkin-Elmer, Foster City, CA, USA), and synthesized by Applied Biosystem (Foster City, CA, USA). Negative controls with no template were performed for each reaction series. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The mRNA levels of CXCR4 gene were represented as copy number/ng total RNA. RT-PCR reaction was carried out using a LightCyclert System (Roche Molecular Biochemicals, Indianapolis, IN, USA). (a) Two primary melanoma cells, P-A and P-B, were infected with reAdGL3CXCR4 or reAdGL3Cox2M. Luciferase activity was determined after 48 h infection. The activity of the Cox2M promoter was set as 1, and the activity of the CXCR4 promoter compared to that induced by the Cox2M promoter. (b) Messenger RNAs were determined by real-time PCR in two primary melanomas, P-A and P-B, and two normal controls, HFBC and HMEC.
Transcriptional targeting via the CXCR4 promoter ZB Zhu et al promoter within the adenoviral vector in melanoma cells, but not in nonmalignant primary dermal melanocytes. Thus, they established tumor specificity of the Cox-2 promoter with potential applications for transcriptional targeting of adenoviral vector-based gene therapy or oncolysis to melanoma. On this basis, we compared the transcriptional activity of the CXCR4 promoter to that of the Cox-2 promoter in melanoma primary cells from two patients (P-A and P-B). The results (Figure 4a) clearly show that the activities of the CXCR4 promoter in two patients were 3.2-and 47-fold higher than that of the Cox-2M promoter, respectively, although the luciferase activity of the CXCR4 promoter was low in two established cell lines, SK-MEL-28 and B16F10 (2.1 and 1.0% of that induced by the CMV promoter). These data were correlated with the results from real-time PCR (Figure 4b ), which revealed that the mRNA levels in two patients were 10 and 94 copies/ng total RNA, respectively, compared to the undetectable levels in two normal cell lines. The data indicated that the CXCR4 promoter is a more powerful tumor-specific promoter for melanomas than the Cox-2 promoter.
In conclusion, the CXCR4 promoter is a promising candidate tumor-specific promoter for melanoma and breast cancers. The activity of the promoter is relatively high in tumor cell lines, and low in the liver and other major organs. This indicates that the CXCR4 promoter is beneficial in cancer therapy with low potential toxicity in vivo and it has a widespread application for many types of cancer types overexpressing CXCR4.
